Trial Profile
An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Behcet's syndrome
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN
- Sponsors Janssen Biotech
- 06 Sep 2018 Status changed from active, no longer recruiting to completed.
- 11 Jul 2018 Planned End Date changed from 9 Aug 2018 to 13 Jul 2018.
- 23 Feb 2018 Status changed from recruiting to active, no longer recruiting.